Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.

There is no fulltext present in this item.

Title:	Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.
Author(s):	Alffenaar, J.W.C.; Laan, T. van der; Simons, S.O. ; Werf, T.S. van der; Kasteele, P.J. van de; Neeling, H. de; Soolingen, D. van
Publication year:	2011
Source:	Antimicrobial Agents and Chemotherapy, vol. 55, iss. 3, (2011), pp. 1287-1289
ISSN:	0066-4804
DOI:	https://doi.org/10.1128/AAC.01297-10
Annotation:	1 maart 2011
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/98382
Display more details
Subject:	N4i 1: Pathogenesis and modulation of inflammation N4i 1: Pathogenesis and modulation of inflammation NCMLS 1: Infection and autoimmunity N4i 3: Poverty-related infectious diseases
Organization:	Pulmonary Diseases Medical Microbiology
Journal title:	Antimicrobial Agents and Chemotherapy
Volume:	vol. 55
Issue:	iss. 3
Page start:	p. 1287
Page end:	p. 1289
Abstract:	Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).